177Lu-Edotreotide (177Lu–Octreotide, 177Lu-Solucin®) is a radiolabeled somatostatin analogue developed for the treatment of NET. It is derived from the equivalent 90Y-Edotreotide originally developed under the name Onalta®.

177Lu-Edotreotide obtained the Orphan Drug designation from the EMA in July 2014 and from the FDA in June 2015 for the indication P-NET (pancreatic neuroendocrine tumors).

177Lu-Edotreotide will be developed for the treatment of patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET). This molecule must be considered as the first competitor for the analogue 177Lu-Octreotate (177Lu-Lutathera®).

A Phase III trial involving 300 patients was initiated in February 2017. This study is supposed to be completed by 2021.

Target/Mechanism: somatostatine receptors

Leading Emitter: beta electrons (β–)